Risks for brain and spinal cord tumours

A risk factor is something that increases the risk of developing cancer. It could be a behaviour, substance or condition. Most cancers are the result of many risk factors. But sometimes brain and spinal cord tumours develop in people who don’t have any of the risk factors described below.

In general, brain and spinal cord tumours are most common in children and older adults. Some types of brain and spinal cord tumours are more common in children and others are more common in adults. Most types of brain and spinal tumours are more common in men. But some types, such as meningiomas, are more common in women.

Some people with certain genetic conditions have a higher than average risk for brain and spinal cord tumours. Talk to your doctor about your risk. If you have a genetic condition that increases the risk of brain and spinal cord tumours, you may need to visit your doctor more often to check for brain and spinal cord tumours. Your doctor will recommend what tests you should have and how often you should have them.

The following are risk factors for brain and spinal cord tumours. All of the risk factors are not modifiable. This means that you can’t change them. Until we learn more about these risk factors, there are no specific ways you can reduce your risk.

Risk factors are generally listed in order from most to least important. But in most cases, it is impossible to rank them with absolute certainty.

Risk factors

Previous radiation therapy

Certain genetic conditions

Family history of brain tumours

Weakened immune system

There is convincing evidence that the following factors increase your risk for brain and spinal cord tumours.

Previous radiation therapy

People who had radiation therapy to the head to treat cancer or another health condition have a higher risk of developing brain tumours.

Certain genetic conditions

People with certain genetic conditions have a higher risk of developing brain and spinal cord tumours:

Neurofibromatosis affects the nerves, muscles, bones and skin. Both neurofibromatosis type 1 (von Recklinghausen disease, or NF1) and neurofibromatosis type 2 (acoustic neuroma, or NF2) increase the risk for brain and spinal cord cancer. But these cancers occur more often in people with NF1. Some research shows that brain and spinal tumours caused by NF2 tend to be slow growing and non-cancerous.

Von Hippel-Lindau (VHL) syndrome is a rare condition where people develop tumours and cysts in many different parts of the body. Tumours may be non-cancerous or cancerous.

Li-Fraumeni syndrome is a rare condition that increases the risk of developing different types of cancer, including brain tumours.

Tuberous sclerosis is also called Bourneville’s disease. It causes non-cancerous tumours to develop in the brain and spinal cord, skin, heart or kidneys.

Turcot syndrome causes many growths, called polyps, to form in the colon. It also causes tumours of the brain and spinal cord.

Basal cell nevus syndrome is also called Gorlin syndrome or nevoid basal cell carcinoma syndrome. It causes problems with several organs and increases the risk of developing different types of tumours, including brain and spinal cord tumours.

Cowden syndrome causes many non-cancerous growths, called hamartomas, to develop in different parts of the body, but most commonly in the skin and mucous membranes. Cowden syndrome increases the risk of developing certain cancers, including brain tumours.

Family history of brain tumours

A family history of brain tumours means that one or more close blood relatives have or had a brain tumour. Some families have more cases of brain tumours than would be expected by chance. Sometimes it is not clear if the family’s pattern of brain tumours is due to chance, shared lifestyle factors, an inherited risk factor that has been passed from parents to children through genes or a combination of these factors.

Weakened immune system

The immune system is a complex group of cells and organs that defend your body against infection, disease and foreign substances. When the immune system isn’t working well, you are at greater risk for primary central nervous system lymphoma (PCNSL). People at high risk include those who:

  • take drugs to suppress their immune system after an organ transplant
  • receive treatments that suppress their immune system, such as chemotherapy, to treat other cancers
  • have HIV or AIDS

Possible risk factors

Using cellphones is a possible risk factor for brain and spinal cord tumours. This means that it has been linked with brain and spinal cord tumours, but there is not enough evidence to show that it is a risk factor.

Questions to ask your healthcare team

To make the decisions that are right for you, ask your healthcare team questions about risks.

Expert review and references

  • American Cancer Society. What are the risk factors for brain and spinal cord tumors?. 2016.
  • American Society of Clinical Oncology. Brain Tumor. 2016.
  • Armstrong T . Central nervous system cancer. Yarbro, CH, Wujcki D, & Holmes Gobel B. (eds.). Cancer Nursing: Principles and Practice. 7th ed. Sudbury, MA: Jones and Bartlett; 2011: 49: pp. 1146-1187.
  • Baan R, Grosse Y, Lauby-Secretan B, et al - International Agency for Research on Cancer Monograph Working Group . Carcinogenicity of radiofrequency electromagnetic fields. Lancet Oncology. Elsevier; 2011.
  • Cancer Research UK. Brain Tumour Risks and Causes. Cancer Research UK; 2014.
  • Cardis, E., Richardson, L., Deltour, I., et al . The INTERPHONE study: design, epidemiological methods, and description of the study population. European Journal of Epidemiology. Springer Netherlands; 2007.
  • Chang S, Mehta M, Vogelbaum M, Taylor M, Ahluwalia M . Neoplasms of the central nervous system. DeVita VT Jr, Lawrence TS, & Rosenberg SA. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015: 97:1412-1455.
  • Clark V, Moliterno Gunel J, Gunel M . Molecular biology of central nervous system tumors. DeVita VT Jr, Lawrence TS, & Rosenberg SA. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015: 96:1403-1411.
  • International Agency for Research on Cancer (IARC). Volume 87: Inorganic and organic lead compounds. 2006: http://monographs.iarc.fr/ENG/Monographs/vol87/mono87.pdf.
  • International Agency for Research on Cancer (IARC). Volume 80: Non-ionizing radiation part 1: static and extremely low frequency (ELF) electric and magnetic fields. 2002: http://monographs.iarc.fr/ENG/Monographs/vol80/mono80.pdf.
  • International Agency for Research on Cancer (IARC). Volume 75: Ionizing Radiation Part 1: X- and Gamma (y)-Radiation, and Neutrons. 2000: http://monographs.iarc.fr/ENG/Monographs/vol75/mono75.pdf.
  • International Agency for Research on Cancer (IARC). Volume 67: Human immunodeficiency viruses and human T-cell lymphotropic viruses. 1996: http://monographs.iarc.fr/ENG/Monographs/vol67/mono67.pdf.
  • International Agency for Research on Cancer (IARC). Volume 70: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. 1997: http://monographs.iarc.fr/ENG/Monographs/vol70/mono70.pdf.
  • International Agency for Research on Cancer (IARC). Volume 97: 1,3-Butadiene, Ethylene Oxide and Vinyl Halides (Vinyl Fluoride, Vinyl Chloride and Vinyl Bromide). 2008: http://monographs.iarc.fr/ENG/Monographs/vol97/mono97.pdf.
  • International Agency for Research on Cancer (IARC). Volume 96: Alcohol Consumption and Ethyl Carbamate. 2010: http://monographs.iarc.fr/ENG/Monographs/vol96/mono96.pdf.
  • International Agency for Research on Cancer (IARC). Volume 99: Some aromatic amines, organic dyes, and related exposures. 2010: http://monographs.iarc.fr/ENG/Monographs/vol99/mono99.pdf.
  • International Agency for Research on Cancer (IARC). Volume 100D: Radiation: A Review of Human Carcinogens. 2011: http://monographs.iarc.fr/ENG/Monographs/vol100D/mono100D.pdf.
  • International Agency for Research on Cancer (IARC). Volume 100F: Chemical Agents and Related Occupations: A Review of Human Carcinogens. 2012: http://monographs.iarc.fr/ENG/Monographs/vol100F/index.php.
  • International Agency for Research on Cancer (IARC). Volume 102: Non-ionizing radiation part 2: radiofrequency electromagnetic fields. 2013: http://monographs.iarc.fr/ENG/Monographs/vol102/mono102.pdf.
  • Macmillan Cancer Support. Brain Tumours - Causes and Risks Factors. 2014: https://www.macmillan.org.uk/.
  • Maule M, Scélo G, Pastore G, et al . Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. Journal of the National Cancer Institute. Oxford University Press; 2007.
  • Meadows AT, Friedman DL, Neglia JP, et al . Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. Journal of Clinical Oncology. American Society of Clinical Oncology; 2009.
  • Mehta M, Vogelbaum MA, Chang S et al . Neoplasms of the Central Nervous System. DeVita VT Jr, Lawrence TS, & Rosenberg SA. Cancer: Principles & Practice of Oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011: 121: 1700-1749.
  • National Cancer Institute. Adult Central Nervous System Tumors Treatment (PDQ®) Health Professional Version. 2017.
  • Neglia JP, Robison LL, Stovall M, et al . New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Journal of the National Cancer Institute. Oxford University Press; 2006.
  • Preston-Martin S, Munir R, & Chakrabarti, I . Nervous system. Schottenfeld, D. & Fraumeni, J. F. Jr. (eds.). Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 4.62: pp. 1173-1195.
  • Rohrmann S, Linseisen J, Becker S, Allen N, et al . Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research; 2011.
  • Ruder AM, Waters MA, Carreon T, et al . The Upper Midwest Health Study: industry and occupation of glioma cases and controls. American Journal of Industrial Medicine. Wiley; 2012.
  • Savitx DA & Trichopoulos . Brain cancer. Adami, H.-O., Hunter, D., & Trichopoulos, D. Textbook of Cancer Epidemiology. 2nd ed. Oxford: Oxford University Press; 2008: 24: pp. 617-635.
  • Shao C, Qi ZY, Hui GZ, et al . Personal hair dyes use and risk of glioma: a meta-analysis. International Journal of Clinical and Experimental Medicine. e-Century Publishing Corporation; 2013.
  • Takkouche B, Etminan M, Montes-Martinez A . Personal use of hair dyes and risk of cancer: A meta-analysis. JAMA: Journal of the American Medical Association. Chicago: American Medical Association; 2005.
  • Yiin JH, Ruder AM, Stewart PA, et al . The Upper Midwest Health Study: a case-control study of pesticide applicators and risk of glioma. Environmental Health. BioMed Central; 2012.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society